Baicalein

SKU: orb1304921

Description

Baicalein

Research Area

Cell Biology, Immunology & Inflammation, Infectious Disease & Virology, Metabolism Research

Key Properties

• CAS Number: 491-67-8
• MW: 270.24
• Purity: 98.48%
• Formula: C₁₅H₁₀O₅
• SMILES: O.Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1
• Target: Influenza Virus,Xanthine Oxidase,ROS,Ferroptosis
• Solubility: DMSO:70.7 mg/mL (261.62 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1.35 mg/mL (5 mM)

Bioactivity

• Target IC50:
  HepG2 cells:28.09 μM|KB-3-1 cells:87.1 μM|MDA-MB-231 cells (48 h):59.50 µM|HT29 cells:18.05 μM|MDA-MB-231 cells (72 h):33.61 µM|HUVECs:3.7 μM|SW48 cells:16.95 μM|XO:3.12 mM.|MDA-MB-231 cells (24 h):89.71 µM|A549 cells:13 μM|3T3-L1 cells:29.81 μM|DLD-1 cells:> 20 μM|KB:62.3 μM|HEK293 cells:4.4 μM|BALB/3T3 cells:342.3 μM
• In Vivo:
  Baicalein effectively reduces graft versus host disease induction without hindering T-cell homeostatic proliferation in mice, demonstrating its significant anti-inflammatory properties in vivo. Further, in rats, baicalein administration guards against elevated heart to body weight ratios, increases in plasma brain natriuretic peptide levels, intraventricular septum thickness, and myocardial collagen volume in the left ventricle (all P<0.05, respectively). Its antifibrotic action is underscored by the reduced expression of pro-collagens I and III in the left ventricle, alongside diminished expression of 12-lipoxygenase, and lowered expression and activity of matrix metallopeptidase 9 and extracellular signal-regulated kinases, thus demonstrating baicalein's capability to inhibit cardiac fibrosis in hypertensive rats.
• In Vitro:
  Baicalein effectively inhibits T cell proliferation and cytokine secretion in response to mitogens in vitro. It has been observed that pre-treatment with baicalein markedly reduces both Con A or anti-CD3/CD28 mAb-induced cell proliferation and cytokine release at a concentration of 25 μM. Additionally, baicalein initiates NF-κB DNA binding while concurrently inhibiting nuclear thioredoxin activity. Furthermore, baicalein hampers the proliferation, migration, and invasion of MDA-MB-231 cells in both a time- and dose-dependent manner, significantly lowering SATB1 expression in these cells. It also diminishes the expression of Wnt1 and β-catenin proteins, along with the transcription of Wnt/β-catenin-regulated genes.
• Cell Research:
  MTT assay is conducted to evaluate the effect of baicalein on proliferation of breast cancer cells. MDA-MB-231 cells are routinely digested, collected, and then seeded in 96-well plates at a density of 8×103 cells/well. After incubation for 12-24 hours, cells are treated with 0, 20, 40, 60, 80, 100, and 120 μM baicalein according to their experimental grouping and then incubated at 37°C for 24, 48, and 72 hours.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Baicalein, 5,6,7-Trihydroxyflavone, Inhibitor, Ferroptosis, InfluenzaVirus, Influenza Virus, inhibit, XO, XanthineOxidase, Xanthine Oxidase

Compound Identifiers

PubChem CID

5702782